Valneva: new data in Covid-19

(CercleFinance.com) - Confirming that it will not invest in new studies for its Covid-19 vaccine, VLA2001, in the absence of a new partnership agreement, Valneva has nevertheless announced new data for this vaccine from ongoing clinical studies.


On 23 February the CHMP of the European Medicines Agency issued a positive opinion for its VLA2001 in 18- to 50-year-olds as a homologous or heterologous booster dose.

New data for its pivotal Phase 3 COV-Compare study showed neutralising antibodies at day 208 were non-inferior to those of the active comparator AZD1222.

In addition, results from VLA2001-304, a Phase 3 study in patients 56 years and older, showed that VLA2001 was well tolerated when administered in two or three doses, confirming its favourable safety profile.

Finally, the vaccine's shelf life was recently extended from 18 to 21 months. The company will continue to submit data for a further extension.


Copyright (c) 2023 CercleFinance.com. All rights reserved.